| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/01/2002 | US6335436 Antisense oligonucleotide coupled to ligand such as d-cycloserine, d-glucosamine, or biotin which binds to receptor on mycobacterium; hybridizes to aspartokinase or aspartate semialdehyde dehydrogenase genes |
| 01/01/2002 | US6335433 nrdD |
| 01/01/2002 | US6335424 ribG |
| 01/01/2002 | US6335363 Administering 4-(sulfonylamino-)-chromane derivative as insecticide, nematocide, fungicide or pesticide for crop protection |
| 01/01/2002 | US6335361 Method of treating benign forgetfulness |
| 01/01/2002 | US6335356 Method of treating a patient by parenteral administration of a lipophilic compound |
| 01/01/2002 | US6335342 Azaindole derivatives, process for their preparation, and their use as antitumor agents |
| 01/01/2002 | US6335323 Administering to the patient a combination of antidepressant or a monoamine oxidase inhibitor, vitamin b12, and precursor or inducer of a neurotransmitter, e.g. l-phenylalanine |
| 01/01/2002 | US6335321 Non-steroidal anti-inflammatory agent therapy for epithelial cell cancer |
| 01/01/2002 | US6335199 Gene therapy |
| 01/01/2002 | US6335194 Antisense modulation of survivin expression |
| 01/01/2002 | US6335028 Implantable particles for urinary incontinence |
| 01/01/2002 | US6335023 Vehicles and oligosaccharide aldonic acids |
| 01/01/2002 | CA2235626C Bactericidal permeability increasing protein (bpi) for treating conditions associated with corneal injury |
| 12/29/2001 | CA2351904A1 Target |
| 12/29/2001 | CA2351897A1 Use of growth hormone secretagogues for treatment of physical performance decline |
| 12/27/2001 | WO2001098518A2 Biotransformation of biologically active compounds made of various classes of chemical substances by means of laccase and manganese peroxidase enzymes |
| 12/27/2001 | WO2001098511A1 Tumour-cell specific gene expression and its use in cancer therapy |
| 12/27/2001 | WO2001098508A2 Transgenic mice containing targeted gene disruptions |
| 12/27/2001 | WO2001098491A2 Osteolevin gene polymorphisms |
| 12/27/2001 | WO2001098486A1 Mutation associated with epilepsy |
| 12/27/2001 | WO2001098478A2 Clk-2, cex-7 and coq-4 genes, and uses thereof |
| 12/27/2001 | WO2001098468A2 Proteases |
| 12/27/2001 | WO2001098354A2 Human receptors |
| 12/27/2001 | WO2001098353A2 Secreted proteins |
| 12/27/2001 | WO2001098351A2 G-protein coupled receptors |
| 12/27/2001 | WO2001098350A2 Compositions comprising net-4 modulations and their use for treating neoplastic disease |
| 12/27/2001 | WO2001098344A2 Angiogenesis-modulating compositions and uses |
| 12/27/2001 | WO2001098332A2 Secreted redox proteins |
| 12/27/2001 | WO2001098330A2 A RECOMBINANT CELL LINE EXPRESSING GPCRx11 AS A FUNCTIONAL RECEPTOR VALIDATED BY ANGIOPEPTIN AND USEFUL FOR SCREENING OF AGONISTS AND ANTAGONISTS |
| 12/27/2001 | WO2001098325A1 Methods for treating and preventing alopecia |
| 12/27/2001 | WO2001098323A2 G-protein coupled receptors |
| 12/27/2001 | WO2001098317A2 Alpha-glycosylceramides for treating bacterial and fungal infections |
| 12/27/2001 | WO2001098299A1 Azaindole derivatives, process for their preparation, and their use as antitumor agents |
| 12/27/2001 | WO2001098294A2 Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
| 12/27/2001 | WO2001098291A2 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders |
| 12/27/2001 | WO2001098286A1 Nitrosated and nitrosylated taxanes, compositions and methods of use |
| 12/27/2001 | WO2001098277A2 Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| 12/27/2001 | WO2001098248A2 Hiv integrase inhibitors |
| 12/27/2001 | WO2001097872A1 Bioadhesive compositions and methods of preparation and use |
| 12/27/2001 | WO2001097860A2 Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy |
| 12/27/2001 | WO2001097856A2 An orphan nuclear receptor |
| 12/27/2001 | WO2001097850A2 Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii) |
| 12/27/2001 | WO2001097849A1 Antitumor effect potentiators |
| 12/27/2001 | WO2001097848A2 Vitronectin receptor antagonist pharmaceuticals |
| 12/27/2001 | WO2001097843A2 Methods for enhancing antibody-induced cell lysis and treating cancer |
| 12/27/2001 | WO2001097834A1 Matrix protein compositions for dentin regeneration |
| 12/27/2001 | WO2001097821A1 Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor. |
| 12/27/2001 | WO2001097819A1 Influenza virus binding, sialylated oligosaccharide substance and use thereof |
| 12/27/2001 | WO2001097818A1 Fortifying vitamin compositions |
| 12/27/2001 | WO2001097811A1 Method for the treatment of overactive bladder |
| 12/27/2001 | WO2001097809A2 Method of treating cardiovascular disease using rapamycin |
| 12/27/2001 | WO2001097808A1 Combinations of depeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabete mellitus |
| 12/27/2001 | WO2001097806A1 Cox-2 inhibitors and the prevention of the side effects of radiation therapy |
| 12/27/2001 | WO2001097799A1 Medium chain fatty acids applicable as antimicrobial agents |
| 12/27/2001 | WO2001097797A1 Paradoxical pharmacology |
| 12/27/2001 | WO2001097793A2 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury |
| 12/27/2001 | WO2001097790A2 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents |
| 12/27/2001 | WO2001097789A2 Pharmaceutical compositions comprising acryloyl distamycin derivatives and topoisomerase i and ii inhibitors |
| 12/27/2001 | WO2001097770A1 Method for protecting human skin |
| 12/27/2001 | WO2001097751A2 New formulation comprising a betablocker and optionally a cholesterol-lowering agent |
| 12/27/2001 | WO2001097749A2 The use of synthetic, non-hormonal 21-aminosteroids and thereof |
| 12/27/2001 | WO2001097627A1 Throat care agents |
| 12/27/2001 | WO2001097618A2 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites |
| 12/27/2001 | WO2001097608A2 Cyk-4 polypeptides, dna molecules encoding them and their use in screening methods |
| 12/27/2001 | WO2001070254A9 Use of human not1 and not1a orphan receptors |
| 12/27/2001 | WO2001070216A3 Diphenyl ketoaldehyde derivatives with anti-hiv activity |
| 12/27/2001 | WO2001060349B1 Pharmacological agent comprising picolinic acid, fusaric acid and derivatives thereof. |
| 12/27/2001 | WO2001049711A3 Nucleic acids encoding (poly)peptides having chips activity |
| 12/27/2001 | WO2001046700A3 Sodium channels as targets for amyloid beta |
| 12/27/2001 | WO2001046256A3 Vesicle trafficking proteins |
| 12/27/2001 | WO2001042488A3 Plasminogen activator assay involving an elastase inhibitor |
| 12/27/2001 | WO2001041771A3 Transdermal system containing acetylsalicylic acid for treatment of migraine |
| 12/27/2001 | WO2001038532A3 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors |
| 12/27/2001 | WO2001037782A3 Method and composition for the treatment of scars |
| 12/27/2001 | WO2001035975A3 Treatment of subnormal bone mineral density |
| 12/27/2001 | WO2001034614A3 Compositions and methods for double-targeting virus infections and targeting cancer cells |
| 12/27/2001 | WO2001003682A3 Use of pyridoxin derivatives for the treatment of diabetes and related complications |
| 12/27/2001 | WO2000064485A3 Specifically targeted catalytic antagonists and uses thereof |
| 12/27/2001 | WO2000054785A9 Stabilized bicyclo[3.3.1]nonenes and methods of use |
| 12/27/2001 | US20010056125 Local anesthetic methods and kits |
| 12/27/2001 | US20010056124 Such as 2-amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol, in free form or as salt to treat organ or tissue allo- or xeno-transplant rejection |
| 12/27/2001 | US20010056122 Therapies for treating pulmonary diseases |
| 12/27/2001 | US20010056112 Synthetic compounds for treatment of inflammation |
| 12/27/2001 | US20010056110 Systemic use of 5-HT3 receptor antagonists against rheumatic inflammatory processes |
| 12/27/2001 | US20010056108 Nitric oxide scavengers, such as dithiocarbamate-containing compounds, are used to reduce side effects caused by therapeutical administration of nitric oxide sources |
| 12/27/2001 | US20010056103 Non-immunosuppressive, piperidino or pyrrolidino amide derivative has an affinity for an FKBP-type immunophilin, useful for treating Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, amyotrophic lateral sclerosis |
| 12/27/2001 | US20010056101 Treatment for disorders stemming from dopamine dysfunction, such as psychosis, schizophrenia, and movement disorders by administration of full or partial dopamine agonist together with dopamine antagonist to prevent side effects |
| 12/27/2001 | US20010056098 Method for stabilizing arylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized arylcarboxylic acid |
| 12/27/2001 | US20010056091 Therapeutic use of a thienylcyclohexylamine derivative |
| 12/27/2001 | US20010056086 Aromatase inhibitors, estrogen receptor antagonists |
| 12/27/2001 | US20010056085 Methods of using vesicant drug formulations |
| 12/27/2001 | US20010056077 Pharmaceutical composition for treatment of duchenne muscular dystrophy |
| 12/27/2001 | US20010056076 Treatment of acute lung injury and fibrosis with antagonists of alphavbeta6 |
| 12/27/2001 | US20010056060 Treatment of osteoporsis with EP2/EP4 receptor selective agonists |
| 12/27/2001 | US20010055782 Enzymatic protein for use in the diagnosis, treatment and prevention of alzheimer's disease and nervous system disorders |
| 12/27/2001 | US20010055777 Potentiation of the immune response |
| 12/27/2001 | US20010055758 Reagents and methods useful for detecting diseases of the prostate |
| 12/27/2001 | US20010055630 Compostion and methods for treating alzheimer's disease and other amyloidoses |
| 12/27/2001 | US20010055627 Compositions And Methods For Regulating Lipoproteins And Hypercholesterolemia With Limonoids, Flavonoids And Tocotrienols |